The tender offer is a modest capital allocation move to clean up the cap table post-merger with Kira Pharmaceuticals. The $0.324 price is well below the $2.92 exercise price, suggesting management views the warrants as unlikely to ever be in the money. Monitor tender results and any subsequent capital structure actions, including the planned stockholder meeting to approve preferred stock conversion and charter amendment.
Price Chart
Executive Summary
Jasper Therapeutics commenced an issuer tender offer to repurchase any and all of its 12,345,707 outstanding warrants (JSPRW) at $0.324 per warrant in cash, for a total of approximately $4.0 million funded from cash on hand. The offer runs from October 7 to November 6, 2026, and aims to reduce potential dilution from warrant exercise, providing greater capital structure certainty. The board approved the offer but makes no recommendation to warrant holders.
Key Financial Metrics
Key Facts
- Jasper offers to buy any and all of its 12,345,707 outstanding warrants at $0.324 per warrant in cash.
- Total consideration if all warrants tendered: approximately $4.0 million, funded from cash on hand.
- Warrants have an exercise price of $2.92 per share and expire on March 18, 2030.
- Offer period: October 7, 2026 to November 6, 2026 (11:59 p.m. ET).
- Board approved the offer but makes no recommendation to holders.
- Three directors hold warrants: Thomas Wiggans (41,000), Judith Shizuru (41,000), Svetlana Lucas (20,000).
- As of September 28, 2026, there were 33,274,561 shares of common stock outstanding.
- Velan Capital Management LLC and affiliates beneficially own 9.9% of common stock.
Financial Impact
Up to $4.0 million cash outflow to retire all warrants; reduces potential dilution by up to 12,345,707 shares (37% of current float).
Risk Factors
- Low tender participation could leave significant warrant overhang.
- Warrants may expire worthless if stock stays below $2.92.
- Cash on hand used for buyback reduces runway for clinical programs.
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-I Filing (Primary) | 0001213900-26-107397 |
| Document: ea030791201ex99-a1b.htm | 0001213900-26-107397 |
| Document: ea0307912-sctoi_jasper.htm | 0001213900-26-107397 |
| Document: ea030791201ex99-a1c.htm | 0001213900-26-107397 |
| Document: ea030791201ex99-a5i.htm | 0001213900-26-107397 |
| Document: ea030791201ex-fee.htm | 0001213900-26-107397 |
| Document: 0001213900-26-107397-index-headers.html | 0001213900-26-107397 |
| Document: 0001213900-26-107397-index.html | 0001213900-26-107397 |
| Document: 0001213900-26-107397.txt | 0001213900-26-107397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | SC TO-I/A | $0.5054 | awaiting T+5 | — | $0.5190 (+2.69%) |
Oct 20, 2026 7d ago | DEF 14A | $0.4999 $0.5189 | ▲ +3.80% | ▲ +3.72% | $0.5190 (+3.82%) |
Oct 15, 2026 12d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5190 (−2.46%) |
Oct 15, 2026 12d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5190 (+2.44%) |
Oct 14, 2026 13d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5190 (+2.46%) |
Oct 7, 2026 20d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5190 (−8.90%) |
Oct 7, 2026 20d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5190 (−8.90%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5190 (+14.79%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5190 (−34.31%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5190 (−17.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers